ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth was artificially inflated through extended payment terms, with actual revenue declining 3% in 2025. The stock fell over 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.